Equities research analysts at StockNews.com assumed coverage on shares of Taro Pharmaceutical Industries (NYSE:TARO – Get Free Report) in a research report issued to clients and investors on Sunday. The brokerage set a “strong-buy” rating on the stock.
Taro Pharmaceutical Industries Price Performance
Taro Pharmaceutical Industries stock opened at $42.97 on Friday. The firm has a market capitalization of $1.62 billion, a PE ratio of 29.84 and a beta of 0.56. The company’s 50-day moving average is $42.61 and its 200-day moving average is $42.26. Taro Pharmaceutical Industries has a fifty-two week low of $32.67 and a fifty-two week high of $45.76.
Taro Pharmaceutical Industries (NYSE:TARO – Get Free Report) last announced its quarterly earnings results on Monday, May 20th. The company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.12. Taro Pharmaceutical Industries had a net margin of 8.56% and a return on equity of 3.75%. The business had revenue of $164.94 million for the quarter, compared to analyst estimates of $156.10 million.
Institutional Trading of Taro Pharmaceutical Industries
Taro Pharmaceutical Industries Company Profile
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.
Further Reading
- Five stocks we like better than Taro Pharmaceutical Industries
- What is the NASDAQ Stock Exchange?
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- MarketBeat Week in Review – 6/24 – 6/28
- What is the Shanghai Stock Exchange Composite Index?
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.